JP2019507793A5 - - Google Patents

Download PDF

Info

Publication number
JP2019507793A5
JP2019507793A5 JP2018547964A JP2018547964A JP2019507793A5 JP 2019507793 A5 JP2019507793 A5 JP 2019507793A5 JP 2018547964 A JP2018547964 A JP 2018547964A JP 2018547964 A JP2018547964 A JP 2018547964A JP 2019507793 A5 JP2019507793 A5 JP 2019507793A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
compound according
heteroaryl
heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018547964A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019507793A (ja
JP6972002B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/021966 external-priority patent/WO2017156495A1/en
Publication of JP2019507793A publication Critical patent/JP2019507793A/ja
Publication of JP2019507793A5 publication Critical patent/JP2019507793A5/ja
Application granted granted Critical
Publication of JP6972002B2 publication Critical patent/JP6972002B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018547964A 2016-03-11 2017-03-10 ブルトン型チロシンキナーゼを調節する化合物及び方法 Active JP6972002B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662307399P 2016-03-11 2016-03-11
US62/307,399 2016-03-11
US201662342004P 2016-05-26 2016-05-26
US62/342,004 2016-05-26
PCT/US2017/021966 WO2017156495A1 (en) 2016-03-11 2017-03-10 Compounds and methods for modulating bruton's tyrosine kinase

Publications (3)

Publication Number Publication Date
JP2019507793A JP2019507793A (ja) 2019-03-22
JP2019507793A5 true JP2019507793A5 (enExample) 2020-05-14
JP6972002B2 JP6972002B2 (ja) 2021-11-24

Family

ID=59789888

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018547964A Active JP6972002B2 (ja) 2016-03-11 2017-03-10 ブルトン型チロシンキナーゼを調節する化合物及び方法

Country Status (13)

Country Link
US (2) US10870652B2 (enExample)
EP (1) EP3426637B1 (enExample)
JP (1) JP6972002B2 (enExample)
KR (1) KR102416971B1 (enExample)
CN (2) CN115746000A (enExample)
AU (1) AU2017230098B2 (enExample)
CA (1) CA3017567A1 (enExample)
ES (1) ES2912465T3 (enExample)
IL (1) IL261583A (enExample)
MX (1) MX388026B (enExample)
PL (1) PL3426637T3 (enExample)
WO (1) WO2017156495A1 (enExample)
ZA (1) ZA201805951B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX388026B (es) * 2016-03-11 2025-03-19 Angel Pharmaceutical Co Ltd Compuestos y métodos para modular la tirosina cinasa de bruton.
JOP20190113A1 (ar) * 2016-11-18 2019-05-15 Biocad Joint Stock Co مثبطات بروتون تيروزين كيناز
CN110494433B (zh) 2017-03-22 2023-03-17 廖细斌 布鲁顿酪氨酸激酶抑制剂
KR102384924B1 (ko) * 2017-07-12 2022-04-08 주식회사 대웅제약 신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물
CN108191871B (zh) * 2018-01-02 2020-02-18 成都倍特药业有限公司 新型布鲁顿酪氨酸激酶抑制剂及其制备方法和应用
TWI767148B (zh) * 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
CN111662232B (zh) * 2019-03-06 2022-08-02 中国科学院上海药物研究所 具有2h-吲唑结构的小分子化合物及其合成和应用
BR112021024131A2 (pt) 2019-05-31 2022-01-11 Haisco Pharmaceuticals Pte Ltd Derivado de anel inibidor de btk, método de preparação para o mesmo e aplicação farmacêutica do mesmo
WO2020252397A1 (en) * 2019-06-12 2020-12-17 Baylor College Of Medicine Small molecule proteolysis-targeting chimeras and methods of use thereof
AU2020355845B2 (en) * 2019-09-26 2023-04-06 Jumbo Drug Bank Co., Ltd. Pyrazolopyridine compounds as selective BTK kinase inhibitors
CN114437078A (zh) * 2020-11-03 2022-05-06 海思科医药集团股份有限公司 一种降解btk的氘代物及其在医药上的应用
CN117377675A (zh) * 2021-06-01 2024-01-09 正大天晴药业集团股份有限公司 含有并环或螺环的布鲁顿酪氨酸激酶降解剂
WO2023009785A1 (en) * 2021-07-29 2023-02-02 Cedilla Therapeutics, Inc. Tead inhibitors and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2001129155A (ru) * 1999-03-26 2003-08-10 Еро-Сельтик С.А. (Lu) Соединения с арильными заместителями (варианты), фармацевтическая композиция и способ лечения расстройства, чувствительного к блокаде натриевых каналов у млекопитающего, способ лечения, профилактики различных заболеваний или уменьшения интенсивности гибели или потери нейронов (варианты), способ облегчения или предупреждения эпилептических припадков у животного (варианты), соединение - радиоактивный лиганд для участка связывания в натриевом канале
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
SE0301906D0 (sv) 2003-06-26 2003-06-26 Astrazeneca Ab New compounds
SI1966151T1 (sl) 2005-12-13 2012-02-29 Schering Corp Policikliäśni indazol derivati, ki so erk inhibitorji
US7659283B2 (en) 2006-02-14 2010-02-09 Vertex Pharmaceuticals Incorporated Pyrrolo [3,2-C] pyridines useful as inhibitors of protein kinases
SG166093A1 (en) 2006-09-22 2010-11-29 Pharmacyclics Inc Inhibitors of brutonæs tyrosine kinase
US8809273B2 (en) * 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
EP2283020B8 (en) * 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituted imidazopyr-and imidazotri-azines
CA2730930C (en) * 2008-07-16 2015-01-13 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
JP5613671B2 (ja) 2008-09-16 2014-10-29 プロキシマジェン エルティーディーProximagen Ltd. 新規化合物ii
EP2464647B1 (en) 2009-08-11 2016-09-21 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
KR101301533B1 (ko) 2010-02-09 2013-09-04 한미사이언스 주식회사 암세포 성장 억제 효과를 갖는 신규 피리미딘 유도체
MX2014000518A (es) 2011-07-13 2014-05-30 Pharmacyclics Inc Inhibidores de la tirosina quinasa de bruton.
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US9458162B2 (en) 2012-01-31 2016-10-04 Nanjing Allgen Pharma Co. Ltd. Cyclic molecules as bruton's tyrosine kinase inhibitors
WO2014022569A1 (en) 2012-08-03 2014-02-06 Principia Biopharma Inc. Treatment of dry eye
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
EP3060218A4 (en) 2013-10-25 2017-07-19 Pharmacyclics LLC Methods of treating and preventing graft versus host disease
WO2015124570A1 (en) 2014-02-18 2015-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of influenza a virus infection
CN108349940B (zh) * 2015-10-14 2021-08-13 淄博百极常生制药有限公司 布鲁顿酪氨酸激酶抑制剂
IL260691B (en) * 2016-01-21 2022-07-01 Zibo Biopolar Changsheng Pharmaceutical Co Ltd Bruton's tyrosine kinase inhibitors
MX388026B (es) * 2016-03-11 2025-03-19 Angel Pharmaceutical Co Ltd Compuestos y métodos para modular la tirosina cinasa de bruton.

Similar Documents

Publication Publication Date Title
JP2019507793A5 (enExample)
JP2020517600A5 (enExample)
EP3209656B1 (en) Indole carboxamides compounds useful as kinase inhibitors
CN115734966A (zh) 杂环化合物及其用途
JP2019514883A5 (enExample)
US9714234B2 (en) Carbazole carboxamide compounds
JP2018505898A5 (enExample)
JP2012507522A5 (enExample)
JP2020505395A5 (enExample)
RU2004111979A (ru) Производные 1н-имидазола, обладающие св1-агонистической, частичной св1-агонистической или св1-антагонистической активностью
JP2020534373A5 (enExample)
JP2019510787A5 (enExample)
JP2008516945A5 (enExample)
JP2018519357A5 (enExample)
JP2009515949A5 (enExample)
JP6672296B2 (ja) 強力なγ−セクレターゼモジュレータ
JP2009539848A5 (enExample)
US10023534B2 (en) Carbazole and tetrahydrocarbazole compounds useful as inhibitors of BTK
JPWO2020012337A5 (enExample)
JP2013542267A5 (enExample)
JP2023534528A (ja) 硫黄含有イソインドリン系誘導体、その調製方法及びその医薬的応用
JP2009515951A5 (enExample)
JP2010520223A5 (enExample)
JP2013544866A5 (enExample)
RU2006103790A (ru) Производные такрина в качестве ингибиторов ацетилхолинэстеразы